Literature DB >> 10442687

Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies.

E A Stronach1, C Clark, C Bell, A Löfgren, N G McKay, V Timmerman, C Van Broeckhoven, N E Haites.   

Abstract

The majority of cases of Charcot-Marie-Tooth type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP) are the result of DNA duplications and deletions respectively of a 1.5 Mb region on 17p11.2. The region contains the peripheral myelin protein 22 gene (PMP-22) and is flanked by homologous proximal and distal CMT1A-REP elements. The majority of duplications and deletions arise during meiotic recombination following misalignment and unequal crossing-over between the proximal and distal CMT1A-REP elements. The cross-over breakpoints are most frequently located within a 1.7 Kb hotspot of recombination and produce novel duplication or deletion junctional CMT1A-REPs with unique restriction patterns. Here we describe the use of PCR based tests, which amplify a 3.6 Kb region including the 1.7 Kb hotspot from specific CMT1A-REPs, for the rapid diagnosis of CMT1A and HNPP patients. In an analysis of 96 CMT1A and 30 HNPP patients, duplication and deletion events were detected in all samples with cross-over breakpoints known to be within the region amplified by PCR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442687

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  8 in total

1.  A comparison of methods for gene dosage analysis in HMSN type 1.

Authors:  J S Rowland; D E Barton; G R Taylor
Journal:  J Med Genet       Date:  2001-02       Impact factor: 6.318

2.  17p duplicated Charcot-Marie-Tooth 1A: characteristics of a new population.

Authors:  Wilson Marques; Marcos R Freitas; Osvaldo J M Nascimento; Acary B Oliveira; Leandro Calia; Ailton Melo; Rita Lucena; Vera Rocha; Amilton A Barreira
Journal:  J Neurol       Date:  2005-03-18       Impact factor: 4.849

3.  An algorithm for genetic testing of Serbian patients with demyelinating Charcot-Marie-Tooth.

Authors:  Milica P Keckarevic Markovic; Jelena Dackovic; Jelena Mladenovic; Vedrana Milic-Rasic; Miljana Kecmanovic; Dusan Keckarevic; Stanka Romac
Journal:  Genet Test Mol Biomarkers       Date:  2012-11-19

4.  Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease.

Authors:  Giorgia Bergamin; Francesca Boaretto; Chiara Briani; Elena Pegoraro; Mario Cacciavillani; Andrea Martinuzzi; Maria Muglia; Andrea Vettori; Giovanni Vazza; Maria Luisa Mostacciuolo
Journal:  Neuromolecular Med       Date:  2014-05-13       Impact factor: 3.843

5.  Effectiveness of real-time quantitative PCR compare to repeat PCR for the diagnosis of Charcot-Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies.

Authors:  Jong Rak Choi; Woon Hyoung Lee; Il Nam Sunwoo; Eun Kyung Lee; Chang Hoon Lee; Jong Baeck Lim
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

6.  A novel PMP22 mutation Ser22Phe in a family with hereditary neuropathy with liability to pressure palsies and CMT1A phenotypes.

Authors:  Kleopas A Kleopa; Domna-Maria Georgiou; Paschalis Nicolaou; Pantelitsa Koutsou; Eleftherios Papathanasiou; Theodoros Kyriakides; Kyproula Christodoulou
Journal:  Neurogenetics       Date:  2004-06-17       Impact factor: 2.660

7.  A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/DHPLC assay.

Authors:  Chia-Yun Lin; Yi-Ning Su; Chien-Nan Lee; Chia-Cheng Hung; Wen-Fang Cheng; Win-Li Lin; Chi-An Chen; Sung-Tsang Hsieh
Journal:  J Hum Genet       Date:  2006-02-04       Impact factor: 3.172

8.  Screening of the 17p11.2--p12 region in a large cohort of patients with Charcot-Marie-Tooth (CMT) disease or hereditary neuropathy with liability to pressure palsies (HNPP).

Authors:  D Kabzinska; J Pierscinska; A Kochanski
Journal:  J Appl Genet       Date:  2009       Impact factor: 2.653

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.